Premium
Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine
Author(s) -
De Dios C.,
Fudio S.,
Lorenzo A.
Publication year - 2011
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/j.1365-2710.2010.01197.x
Subject(s) - quetiapine , valproic acid , parkinsonism , concomitant , quetiapine fumarate , bipolar disorder , medicine , drug interaction , psychiatry , drug , cognition , pharmacology , schizophrenia (object oriented programming) , disease , atypical antipsychotic , epilepsy , antipsychotic
Summary What is known and Objective: Combination therapy with valproic acid plus quetiapine is recommended as one of the first‐line approaches to treatment of manic or mixed episodes in patients with bipolar disorder. Case summary: A 66‐year‐old patient with this psychiatric disease developed parkinsonism and cognitive decline during concomitant treatment with both drugs. The rapid onset of symptoms soon after use of the combination suggested an interaction/using the Karch‐Lasagna criteria, the interaction was judged to be definite. What is new and Conclusion: Their evidence on a pharmacokinetic drug interaction between the two drugs is conflicting but possible underlying mechanisms proposed include CYP3A4 inhibition. As concomitant use of valproate and quetiapine is now quite frequent in bipolar disorder, this potential interaction should be closely monitored, especially in the elderly.